Both dual bronchodilation and triple therapy demonstrated similar rates of mortality in patients with moderate to severe COPD at low risk for exacerbations. Both dual bronchodilation and triple ...
February 28, 2007 (San Diego) — Combined therapy with the inhaled corticosteroid budesonide and the long-acting beta-agonist formoterol ( Symbicort) produces bronchodilation as rapidly as does ...
May 27, 2009 (San Diego, California) — The novel once-daily inhalation β 2-agonist indacaterol was well tolerated, had safety profiles similar to placebo (both at 150 μg and 300 μg doses), and ...
Pearl Therapeutics' PT003 Combination Therapy for COPD Demonstrates Superior Bronchodilation Compared to Spiriva® and Foradil® in Randomized Phase 2b Study REDWOOD CITY, Calif., Dec. 1, 2010 ...
Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE ...
Please provide your email address to receive an email when new articles are posted on . There is a need for a nebulized LABA/LAMA formulation in COPD. Bronchodilation, pharmacokinetics and safety of a ...
Figure 1: Effect of chloroquine on BK channel currents in mouse airway smooth muscle cells. Figure 2: Lack of an effect of BK channel blockers on bitter tastant–induced relaxation in mouse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results